The 2025 edition · 52 pages
Annual Reference · 2025 Edition
China Pharmaceutical Innovation Archive
The definitive annual reference on China’s pharmaceutical innovation landscape — the regulatory reforms, insurance negotiations and licensing deals that reshaped the world’s second-largest drug market.
PDF $599 · Hardcopy $599 · Published by Fineline BioInsights
2024 · The Year in Numbers
A market that moved from follower to source.
Every figure above is traced to a primary regulatory source inside the Archive — with the underlying tables reproduced in full.
02 — Inside the Archive
Not commentary. Evidence.
Actual pages from the 2025 edition. The Archive reproduces the approval records, negotiation outcomes and deal tables behind every conclusion.
Structure of the 2025 edition
- 012024 Yearly Hotspots ReviewEight features: record approvals, NRDL negotiations, the 10th VBP round, outbound licensing, patent term extension, the Class C drug list.
- 02China’s Pharmaceutical Development HistoryThe reform decades behind today’s market — from the 1979 rules to the 2015 overhaul and its aftermath.
- 03Enterprise Strategic TransformationHow multinationals and domestic players are repositioning for a China that now exports innovation.
- 04Outlook for 2025Policy direction, payment reform and the cross-border deal pipeline to watch.
03 — Methodology
Research you can trace.
Primary regulatory sources
NMPA approval records, NHSA negotiation outcomes and official policy documents — read in the original, not through secondhand summaries.
Official approval data
Every approval, designation and reimbursement decision in the Archive is drawn from the regulator’s own published data.
Verified transaction records
Licensing deals are checked against company disclosures and verified records. Where a figure is provisional or estimated, the report says so.
“We do not publish speculation.” Fineline BioInsights · Research Methodology
04 — Editorial Team
The people behind the Archive.
Karia Olsen
Pharmaceutical industry analyst with 15 years of experience. Master’s degree in Pharmacy from Fudan University; a decade at a multinational pharmaceutical consultancy.
Emily Zhang
Responsible for the Archive’s data visualisation and publication design — every chart rebuilt for clarity and traceability.
Leona Zeng
Oversees fact-checking, source verification and the production of each edition in PDF and hardcopy.
Fineline BioInsights is the pharmaceutical research and publishing division of Fineline Information & Technology. All reports are company publications; copyright belongs to Fineline Information & Technology.
05 — Coverage Areas
Four lenses on one market.
- 01
Regulatory Affairs
NMPA approval trends, priority review, breakthrough therapy designations and patent term extensions.
- 02
Market Access
NRDL negotiations, volume-based procurement and the pricing dynamics shaping patient access.
- 03
BD & Licensing
License-out transactions, NewCo structures and the cross-border deals driving China’s global rise.
- 04
Policy & Trade
Industrial policy, U.S.–China trade developments and their impact on the global drug market.
The 2025 Edition
The year China’s drug industry changed — documented.
One annual volume. Every approval, every negotiation, every deal that mattered — traced to its source.
PDF $599 · Hardcopy $599 · Institutional enquiries welcome
